ImClone, Merck Reach Deal Over Erbitux
Under the terms of the deal, which was announced Thursday, ImClone gave Merck permission to sublicense certain intellectual property rights to Japanese drug maker Takeda Pharmaceutical Co.
Takeda and Merck had signed an alliance last September regarding the anti-EGFR antibody Matuzumab.
“These agreements will allow Merck and Takeda to move...
To view the full article, register now.